Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US10870703B2 · kind B2 · utility
2Cited by
0References
82Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2018 |
| Grant date | Dec 22, 2020 |
| Priority date | — |
| Expiry date | Oct 2, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGM-CSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGM-CSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.